Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CAREMAX Aktie jetzt für 0€ handeln | |||||
21.02. | CareMax, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
18.11.24 | CareMax Reaches Agreements to Sell Management Services Organization and Core Centers' Assets | 212 | Business Wire | MIAMI--(BUSINESS WIRE)--CareMax, Inc. (NASDAQ: CMAX; CMAXW) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced it has entered into an agreement... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INTUITIVE SURGICAL | 407,20 | -0,61 % | ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue? | ||
UNITEDHEALTH | 227,55 | +1,54 % | UnitedHealth: Jetzt ist Einstiegszeit! | Der US-amerikanische Gesundheitskonzern UnitedHealth Group befindet sich in einem spannenden Spannungsfeld zwischen steigenden Gesundheitskosten und innovativen Kostensenkungsstrategien. Anstatt diese... ► Artikel lesen | |
THERMO FISHER | 412,10 | +0,75 % | Plattform-Strategien krempeln Biotech-Markt um: BioNxt, Thermo Fisher Scientific, Evotec | Bei Biotech gilt längst nicht mehr das Prinzip alles oder nichts. Statt nur ein Produkt im Angebot zu haben, setzt sich bei der Entwicklung der Wirkstoffe von morgen die Plattform-Ökonomie durch. Was... ► Artikel lesen | |
ROKU | 72,22 | -0,01 % | Roku's Next Bet: Launching the Cheapest Ad-Free Streaming Service | ||
ATOSSA THERAPEUTICS | 0,680 | +2,72 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
CENTENE | 22,515 | +0,54 % | Sarah London, youngest CEO in Fortune 500 with US$20.6mn salary: Sarah London leads Centene, becoming youngest ... | ||
VERU | 0,298 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA8959792018 Trilogy AI Corp. 08.08.2025 CA88909Q1090 Tokenwell Platforms Inc. 11.08.2025 Tausch 1:1US92536C1036 Veru... ► Artikel lesen | |
QUIDELORTHO | 21,400 | 0,00 % | QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand | ||
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
NANO-X IMAGING | 4,465 | 0,00 % | Nano-X Imaging Non-GAAP EPS of -$0.17 misses by $0.02, revenue of $3.04M misses by $0.16M | ||
FULGENT GENETICS | 18,000 | 0,00 % | Fulgent Genetics: UBS stuft Aktie auf 'Kaufen' hoch und verweist auf Wachstumspotenzial | ||
LANTHEUS | 45,100 | -2,28 % | Pre-market Movers: Myriad Genetics, LifeMD, Evolus, Lantheus Holdings, Astera Labs | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04.
Astera... ► Artikel lesen | |
PERSPECTIVE THERAPEUTICS | 3,160 | -7,06 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results | [212Pb]VMT-a-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date:... ► Artikel lesen | |
AMN HEALTHCARE SERVICES | 14,900 | +3,47 % | AMN Healthcare Services Inc: AMN Healthcare Announces Second Quarter 2025 Results | Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc.... ► Artikel lesen |